-
公开(公告)号：US20230321212A1
公开(公告)日：2023-10-12
申请号：US18042561
申请日：2021-08-23
申请人： Pfizer Inc.
发明人： Annaliesa Sybil Anderson , Robert George Konrad Donald , Julio Cesar Hawkins , Srinivas Kodali , Raphael Simon
CPC分类号： A61K39/092 , A61P37/04 , A61K2039/6031
摘要： The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号：US20230173051A1
公开(公告)日：2023-06-08
申请号：US17917624
申请日：2021-04-09
申请人： Valneva Austria GmbH , Pfizer Inc.
发明人： Nicole Bézay , Romana Hochreiter , Urban Lundberb , Steven Russell Bailey , Annaliesa Sybil Anderson , Kathrin Ute Jansen , Daniel Alfred Scott
CPC分类号： A61K39/0225 , A61P37/04 , A61K2039/55505
摘要： The present invention relates to a composition comprising the OspA fusion protein of SEQ ID NO: 1 (LipSID1-S2D1), the OspA fusion protein of SEQ ID NO: 2 (Lip-S4D1-SShybD1) and the OspA fusion protein of SEQ ID NO: 3 (Lip-S5D1-S6D1) for use in a vaccine or for use in a method for eliciting an immune response in a human against Lyme disease.
-
公开(公告)号：US20220118072A1
公开(公告)日：2022-04-21
申请号：US17428487
申请日：2020-02-07
申请人： Pfizer Inc.
发明人： Annaliesa Sybil Anderson , Paul Liberator , Thomas Richard Jones , Kathrin Ute Jansen , John Lance Perez , Shannon Lea Harris
IPC分类号： A61K39/095 , A61K47/26 , A61K47/22 , A61K47/02
摘要： In one aspect, the invention relates to use of a composition including a first polypeptide and a second polypeptide, wherein the composition elicits an immune response against Neisseria meningitis serogroup B strains expressing, for example, variants A02, A28, A42, A63, A76, B05, B07, B08, B13, B52 and B107.
-
公开(公告)号：US11208633B2
公开(公告)日：2021-12-28
申请号：US16704744
申请日：2019-12-05
申请人： Pfizer Inc.
发明人： Jason Arnold Lotvin , Annaliesa Sybil Anderson , Robert G. K. Donald , Michael James Flint , Narender Kumar Kalyan , Kathrin Ute Jansen , Maninder K. Sidhu , Justin Keith Moran , Mark Edward Ruppen , Weiqiang Sun
摘要： In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.
-
公开(公告)号：US20210101943A1
公开(公告)日：2021-04-08
申请号：US17126712
申请日：2020-12-18
申请人： Pfizer Inc.
发明人： Annaliesa Sybil Anderson , Rasappa Gounder Arumugham , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Kathrin Ute Jansen , Thomas Richard Jones , Lakshmi Khandke , Bounthon Loun , John Lance Perez , Gary Warren Zlotnick
IPC分类号： C07K14/22 , A61K39/13 , A61K39/295 , A61K39/00 , A61K39/095 , A61K39/12 , A61K39/39 , C12N7/00
摘要： In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
-
公开(公告)号：US10946086B2
公开(公告)日：2021-03-16
申请号：US16245378
申请日：2019-01-11
申请人： Pfizer Inc.
发明人： Annaliesa Sybil Anderson , Amardeep Singh Bhupender Bhalla , Robert G. K. Donald , Jianxin Gu , Kathrin Ute Jansen , Rajesh Kumar Kainthan , Lakshmi Khandke , Jin-Hwan Kim , Paul Liberator , Avvari Krishna Prasad , Mark Edward Ruppen , Ingrid Lea Scully , Suddham Singh , Cindy Xudong Yang
IPC分类号： A61K39/09 , A61K39/39 , A61K39/40 , A61K39/00 , C07K16/12 , C07K16/44 , A61K47/10 , A61K47/26
摘要： The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号：US20210024589A1
公开(公告)日：2021-01-28
申请号：US17060067
申请日：2020-09-30
申请人： PFIZER INC.
发明人： Annaliesa Sybil Anderson , Susan Kay Hoiseth , Kathrin Ute Jansen , Justin Keith Moran , Mark Edward Ruppen
IPC分类号： C07K14/22 , A61K39/095
摘要： In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.
-
8.发明申请公开(公告)号：US20200254081A1
公开(公告)日：2020-08-13
申请号：US16647124
申请日：2018-09-14
申请人： Pfizer Inc.
发明人： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Robert G.K. Donald , Michael James Flint , Nicholas Randolph Everard Kitchin , Justin Keith Moran , Louise Pedneault , Michael W. Pride , Mark Edward Ruppen , Christopher Frederick Webber
摘要： In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, wherein the second administration is about 30 days after the first administration, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.
-
公开(公告)号：US10543267B2
公开(公告)日：2020-01-28
申请号：US16196150
申请日：2018-11-20
申请人： PFIZER INC.
发明人： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Judith Absalon , Jose Miguel Aste-Amezaga , Johannes Frederik Beeslaar , David Cooper , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Thomas Richard Jones , Isis Kanevsky , Lakshmi Khandke , Paul Liberator , John Lance Perez , Lynn Marie Phelan , Gary Warren Zlotnick
IPC分类号： A61K39/095 , A61K31/7028 , A61K47/10 , A61K47/18 , C07K14/22 , C07K16/12 , A61K47/26 , A61K47/64 , A61P31/00
摘要： In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.
-
公开(公告)号：US20190142922A1
公开(公告)日：2019-05-16
申请号：US16245378
申请日：2019-01-11
申请人： Pfizer Inc.
发明人： Annaliesa Sybil Anderson , Amardeep Singh Bhupender Bhalla , Robert G.K. Donald , Jianxin Gu , Kathrin Ute Jansen , Rajesh Kumar Kainthan , Lakshmi Khandke , Jin-Hwan Kim , Paul Liberator , Avvari Krishna Prasad , Mark Edward Ruppen , Ingrid Lea Scully , Suddham Singh , Cindy Xudong Yang
摘要： The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
-
-
-
-
-
-
-
-
搜索结果
74 条记录 (耗时 0.04 秒)
